FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

EMD Serono NDA for Lung Cancer

[ Price : $8.95]

FDA accepts for priority review an EMD Serono NDA for once-daily, orally-dosed tepotinib for treating certain adult patients with ...

Praise for PDUFA, Suggestions for Improvement

[ Price : $8.95]

Five major stakeholders praise PDUFA performance to date and suggest improvements to be included in the 2022 PDUFA 7 reauthorizati...

Trump Turned Science into Political Hot Potato: Op-Ed

[ Price : $8.95]

Former FDA commissioner Margaret Hamburg and principal deputy commissioner Joshua Sharfstein say the Trump administration and FDA ...

Ipsen Plans Palovarotene NDA After Post Hoc Analysis

[ Price : $8.95]

Ipsen says it is planning to submit an NDA for palovarotene and its use in treating patients with fibrodysplasia ossificans progre...

FDA Taking Steps on Rifampin, Rifapentine Shortages

[ Price : $8.95]

FDA says it will temporarily allow the distribution of some rifampin and rifapentine with nitrosamine impurities to avoid shortage...

Who is Helping Hahn with Communication Efforts?

[ Price : $8.95]

FDA commissioner Stephen Hahns controversial remarks exaggerating the efficacy of convalescent plasma touches off a wider examinat...

FDA Nixes Amputation Boxed Warning on Canagliflozin

[ Price : $8.95]

FDA says it is removing a Boxed Warning about amputation risk on Janssens diabetes drug canagliflozins (Invokana, Invokamet, Invok...

CBER Updates CY 2020 Guidance Agenda

[ Price : $8.95]

CBER updates its Calendar Year 2020 guidance agenda listing 28 planned guidances in four categories.

Transfer of Ownership MAPP

[ Price : $8.95]

CDER publishes a MAPP describing responsibility in the Office of Generic Drugs for processing drug application ownership changes i...

CGMP Violations at Custom Nutraceuticals

[ Price : $8.95]

FDA warns Custom Nutraceuticals about CGMP violations that adulterate its dietary supplements.